Nanoviricides, Inc.

Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides

Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides

NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete

MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides

Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides